PsA: Depressing News on Second- and Later-Line Treatments Most patients with PsA failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated. https://t.co/7tSzoNLVoD https://t.co/3oUM4E38b1